Clinical Trial Update: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Q702, an oral Axl/Mer/CSF1R tyrosine kinase inhibitor, in combination with pembrolizumab, for selected advanced solid tumors includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Esophageal Cancer
• Gastric Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Q702

Snippet

Sponsor: Qurient Co., Ltd. | Conditions: Esophageal Cancer, Gastric Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING